Suggested remit: To appraise the clinical and cost effectiveness of bepirovirsen within its marketing authorisation for treating chronic hepatitis B.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6608
Provisional Schedule
- Committee meeting: 1:
- 12 January 2027
- Expected publication:
- 10 March 2027
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- GlaxoSmithKline (bepirovirsen)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Addiction Recovery Agency
- African Health Policy Network (AHPN)
- Black Health Agency for Equality
- British Liver Trust
- Compass UK
- Hepatitis B Trust
- HepB Companion
- HIV i-Base
- LGBT Hero
- Liver4Life
- LIVErNORTH
- National AIDS Trust
- Positively UK
- Release
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Terrence Higgins Trust
- The Hepatitis C Trust
- We Are With You
- Professional groups
- British Association for Sexual Health and HIV
- British Association for the Study of the Liver (BASL)
- British Geriatrics Society
- British Hepatology Pharmacy Group
- British HIV Association
- British Society for Gastroenterology
- British Viral Hepatitis Group
- Matthews lab HBV Elimination Laboratory (The Francis Crick Institute)
- NIHR Health Protection Research Unit in Evaluation and Behavioural Science University of Bristol
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- UK Clinical Virology Network
- UK Harm Reduction Alliance
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Aristo Pharma (entecavir)
- Aurobindo Pharma (entecavir, tenofovir disoproxil)
- Bristol Myers Squibb (entecavir)
- Cipla (entecavir)
- Dr. Reddy’s Laboratories (tenofovir disoproxil)
- Gilead Sciences (tenofovir disoproxil)
- Glenmark Pharmaceuticals (entecavir)
- Orion Pharma (tenofovir disoproxil)
- Pharmaand (peginterferon alfa-2a)
- Sandoz (tenofovir disoproxil)
- Sun Pharma UK (entecavir)
- Thornton & Ross (tenofovir disoproxil)
- Viatris (tenofovir disoproxil)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Haemophilia Wales
- Healthcare Improvement Scotland
- Hepatitis Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS England Viral Hepatitis Elimination Programme
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Scottish Society of Gastroenterology
- Welsh Government
- Relevant research groups
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health & Care Research
- UCL Centre for Sexual Health & HIV Research
- UK National Screening Committee
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 June 2026 | Invitation to participate |
| 06 March 2026 - 07 April 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6608 |
| 06 March 2026 | In progress. Scoping commencing |
| 26 September 2025 | Awaiting development. We anticipate that the appraisal will begin in early June 2026 when we will write to stakeholders about how to get involved. |
| 20 June 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual